Solubility of montelukast (as a potential treatment of COVID -19) in supercritical carbon dioxide: Experimental data and modelling

Preparation of Erlotinib hydrochloride nanoparticles (anti-cancer drug) by RESS-C method and investigating the effective parameters

The size of the drug particles is one of the essential factors for the proper absorption of the drug compared to the dose of the drug. When particle size is decreased, drug uptake into the body increases. Recent studies have revealed that the rapid expansion of supercritical solution with cosolvent plays a significant role in preparing micron and submicron particles. This paper examines the preparation of Erlotinib hydrochloride nanoparticles using a supercritical solution through the cosolvent method for the first time. An examination of the parameters of temperature (318-338 K), pressures (15-25 MPa) and nozzle diameter (300-700 μm) was investigated by Box-Behnken design, and their respective effects on particle size revealed that the nozzle diameter has a more significant impact on particle size than the other parameters. The smallest particles were produced at temperature 338 K, pressure 20 MPa, and nozzle diameter 700 μm. Besides, the ERL nanoparticles were characterized using SEM, DLS, XRD, FTIR, and DSC analyses. Finally, the results showed that the average size of the ERL particles decreased from 31.6 μm to 200-1100 nm.

Improving and measuring the solubility of favipiravir and montelukast in SC-CO2 with ethanol projecting their nanonization

Supercritical carbon dioxide (SC-CO2)-based approaches have become more popular in recent years as alternative methods for creating micro- or nanosized medicines. Particularly, high drug solubility is required in those techniques using SC-CO2 as a solvent. During the most recent pandemic years, favipiravir and montelukast were two of the most often prescribed medications for the treatment of COVID-19. In this study, ethanol at 1 and 3 mol% was utilized as a cosolvent to increase the solubility of both medicines in SC-CO2 by a static approach using a range of temperatures (308 to 338 K) and pressure (12 to 30 MPa) values. The experimentally determined solubilities of favipiravir and montelukast in SC-CO2 + 3 mol% ethanol showed solubility values up to 33.3 and 24.5 times higher than that obtained for these drugs with only SC-CO2. The highest values were achieved in the pressure of 12 MPa and temperature of 338 K. Last but not least, six density-based semi-empirical models with various adjustable parameters were used to perform the modeling of the solubility of favipiravir and montelukast.

Experimental and modeling of solubility of sitagliptin phosphate, in supercritical carbon dioxide: proposing a new association model

The solubility of an anti-hyperglycemic agent drug, (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4] triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine (also known as Sitagliptin phosphate) in supercritical carbon dioxide (scCO2) was determined by ananalytical and dynamic technique at different temperatures (308, 318, 328 and 338 K) and pressure (12-30 MPa) values. The measured solubilities were in the range of 3.02 × 10-5 to 5.17 × 10-5, 2.71 × 10-5 to 5.83 × 10-5, 2.39 × 10-5 to 6.51 × 10-5 and 2.07 × 10-5 to 6.98 × 10-5 in mole fraction at (308, 318, 328 and 338) K, respectively. The solubility data were correlated with existing density models and with a new association model.